Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2025
Pharma News, 2025
China's Everest Medicines
China's Everest Medicines Unveils Positive Preclinical Validations of In Vivo CAR-T Program
Harmony Biosciences Preclinical Data for Narcolepsy Drug BP1.15205 Shows Promise
Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) is one of the most undervalued small-cap stocks to buy according to analysts.
Klotho Neurosciences’ ALS therapy awarded FDA Orphan Drug Designation
Klotho Neurosciences announced that its novel therapy KLTO-202, also known as s-KL-AAV.myo, for the treatment of Amyotrophic Lateral Sclerosis (ALS) has received Orphan
Trump’s 200% tariff
Trump’s 200% tariff threat could send shockwaves through pharma supply chains
Merck spends $10 billion for Verona, gaining access to its COPD medication
Pharmaceutical giant Merck is buying Verona Pharma, a company that focuses on respiratory diseases, in an approximately $10 billion deal.
Artelo Biosciences’ ART12.11
Artelo Biosciences’ ART12.11 Shows Promising Antidepressant Effects in Preclinical Study
Silo Pharma Advances PTSD Drug SPC-15
Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025
Cyclacel announces publication of preclinical data on plogosertib
Cyclacel Pharmaceuticals (CYCC) highlighted a publication from independent investigators titled, “DNAJ-PKAc fusion heightens PLK1 inhibitor sensitivity in fibrolamellar carcinoma,” publish...
Mustang Bio Granted
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma
Alembic Pharmaceuticals acquires UTILITY therapeutics
Alembic Pharmaceuticals has acquired UTILITY therapeutics, expanding its portfolio with the addition of Pivya (pivmecillinam 185 mg tablets), a penicillin class antibacterial for treating unco...
CAR-T cells engineered to attack two leukemia proteins show promise in preclinical tests
T-cell acute lymphoblastic leukemia (T-ALL) is a highly aggressive form of blood cancer that can occur in both children and adults.
FDA approves Gamifant for macrophage activation syndrome in Still’s disease
The US Food and Drug Administration (FDA) has approved Gamifant (emapalumab-lzsg) for the treatment of macrophage activation syndrome (MAS) in adult and paediatric patients wit...
22
23
24
25
26
27
28
29
30
